EHS
EHS

STAT+: Pharmalittle: Biden plan to stretch monkeypox vax supplies hits problems; Pfizer and BioNTech ask FDA to clear Covid shot for variants



Top of the morning to you, and a fine one it is. After a much-needed spot of rain, blue skies and comfortable breezes are enveloping the Pharmalot campus, where the short person is sleeping in and the official mascot is dozing in a corner. As for us, we are engaged in the usual rituals — firing up the coffee kettle in order to brew a cup of stimulation (the choice today pecan bourbon) and foraging for items of interest. On that note, here are a few tidbits to help you get started on your journey today, which we hope will be meaningful and productive. Meanwhile, do keep in touch — we enjoy secret dossiers and saucy tips …

Pfizer and BioNTech asked the Food and Drug Administration to clear use of a Covid-19 shot modified to target the newest versions of the Omicron variant, STAT says. The agency is expected to clear the shots for use in the coming weeks, in time for a planned fall booster campaign. The Pfizer-BioNTech booster shot targets the original coronavirus plus the BA.4 and BA.5 subvariants of Omicron, which have become predominant in the U.S. Pfizer and BioNTech said they have begun producing doses of the vaccines, and could begin supplying them to the U.S. government upon FDA clearance for a vaccination campaign that could start as soon as September.

Continue to STAT+ to read the full story…



Source link

EHS
Back to top button